Detection of pretreatment circulating tumor DNA as a biomarker of poor outcome in intermediate-risk rhabdomyosarcoma

Fariba Navid,Jaclyn A. Biegel

DOI: https://doi.org/10.21037/tp-24-7

2024-05-31

Translational Pediatrics

Abstract:Fariba Navid 1,2 , Jaclyn A. Biegel 2,3 1 Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA; 2 Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; 3 Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA Comment on: Abbou S, Klega K, Tsuji J, et al . Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol 2023;41:2382-93. Keywords: Circulating tumor DNA (ctDNA); rhabdomyosarcoma (RMS); FOXO1 fusion; outcomes Submitted Jan 12, 2024. Accepted for publication Apr 09, 2024. Published online May 28, 2024. doi: 10.21037/tp-24-7 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, representing about 3% of pediatric malignancies. Approximately 350 new cases are diagnosed in children and adolescents per year in the United States with almost two-thirds of cases presenting in patients younger than 6 years of age with another peak in adolescents (1). The tumor can occur in any site of the body. There are two main and distinct histologic subtypes of RMS, alveolar and embryonal. The alveolar subtype is often associated with recurring translocations involving the PAX3 or PAX7 gene on chromosome 2 or 1 with the FOXO1 gene on chromosome 13. Because not all RMS with features of alveolar subtype histology harbor these translocations and behave more like the favorable embryonal subtype, the disease classification of RMS has been further refined to FOXO1 fusion-positive RMS (FP-RMS) and FOXO1 fusion-negative RMS (FN-RMS) (2,3). The treatment for RMS is multimodal, including chemotherapy, surgery and/or radiation therapy, and is tailored based on risk group assignment. The Children's Oncology Group risk group assignments are designated as very low, low, intermediate, and high and are based on clinical, pathological, and more recently molecular features. Patients with very low or low risk disease have excellent outcomes of over 90% survival. Those with high-risk disease have a dismal prognosis of less than 20% survival. Patients with intermediate-risk (IR) disease represent the largest and most heterogenous group with survival ranging from 50–70% (4,5). The article by Abbou et al. (6) published in the Journal of Clinical Oncology entitled "Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group" explores the detection of circulating tumor DNA (ctDNA) in pretreatment serum samples in patients with newly diagnosed IR RMS as a potential biomarker of prognosis in IR RMS, including FP-RMS and FN-RMS. FP-RMS is defined by a PAX3/7 gene fusion and less frequent copy number alterations (CNAs) and FN-RMS is defined by aneuploidy in nearly every tumor, and single nucleotide variants (SNVs) in a small number of genes (7). Due to this heterogeneity of molecular alterations, the authors used two methods, ultralow passage whole genome sequencing (ULP-WGS) for detecting CNAs and an RMS-specific hybrid capture assay (Rhabdo-Seq) to identify translocations and SNVs in 22 RMS-relevant genes. The lower level of detection of ctDNA for these assays is reported to be 3% of the total of cell-free DNA for ULP-WGS and 0.4% for the Rhabdo-Seq assay. A total of 124 patient samples from patients enrolled on the Children's Oncology Group biology study D9902 who had clinical characteristics similar to patients with IR RMS treated on the Children's Oncology Group (COG) trial ARST0531 (8) were analyzed, 75 from patients with FN-RMS and 49 from FP-RMS. Tumor tissue was available for 69 and 35 patients, respectively. Tumor tissue testing is relevant for studies evaluating ctDNA because in general, if the tumor does not have CNAs, then ULP-WGS is uninformative. Similarly, if the specific SNVs or translocations assessed by Rhabdo-Seq are not present in the tumor, the assay is uninformative. However, as with the current study, there are circumstances when ctDNA may be detectable when the tumor was not informative. This situation is likely due to the heterogeneity of the tumor, such that the molecular abnormality may not have been present or present at below the assay level of detection in the area of the tumor that was sampled for testing. The yield of potentially detecting a more comprehensive assessment of the genetic landscape of a tumor may be higher if multiple sections from histologically diverse are included for assessment. In patients with FN-RMS (n=75), the authors report the detection of ctDNA in 23 patients (31%) by either assay, 13 patients (17%) by ULP-WGS and 18 patients (24%) by Rhabdo-Seq. Molecular profiling of the available tumor tissue in FN-RMS showed detect -Abstract Truncated-

pediatrics